| Health systems are facing pressures to | Because |
|---|---|
| Expand early detection efforts at scale | More than 2 million new cancer diagnoses expected in 2026 |
| Improve outcomes and reduce cost of care through screening | Earlier diagnosis has contributed to increased survival for some cancers by increasing the likelihood of treatment success |
| Provide high-quality care despite staffing and capacity constraints | Innovative, noninvasive, low-cost solutions may help increase cancer screening uptake |
| Meet population health, equity, and quality goals | Increasing access to cancer screenings may help address health disparities |
Cancer screening solutions
Exceptional cancer care starts with early detection
Loading component...
Navigating the challenges of colorectal cancer screening
The rising incidence of colorectal cancer (CRC) in people younger than 55 years prompted the USPSTF and other organizations to lower the recommended screening age from 50 to 45 years.4,5 Yet CRC screening using colonoscopy alone cannot close the screening gap.6 Is your health system prepared to meet this challenge?
We can provide a complete CRC screening solution designed with better patient outcomes in mind1,7
The Cologuard Plus® test: screening with the Cologuard® test can help your system achieve quality and population health goals, while supporting key priorities and initiatives:
- Adhere to clinical guidelines and improve quality measure performance
4,5,8 - Enhance patient experience and screening completion rates
9,10 - Ensure access and affordability
8
Visit the healthcare provider page to learn more about the test
The SimpleScreen™ CRC test: an FDA-approved, blood-based CRC screening option for average-risk patients 45+
- Meets patients where they are by offering a trusted experience and CRC screening option to those who decline or will not complete ACS-preferred testing
† - Together with the Cologuard test, the SimpleScreen test can help close the screening gap and reach those who remain unscreened
Visit the healthcare provider page to learn more about the test
Real-world experience
See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.
Advancing early detection with the Cancerguard® multi-cancer early detection (MCED) test
The Cancerguard test complements standard-of-care screening and can help detect multiple cancers with a simple blood draw.
- Designed to help detect 50+ cancer types and subtypes by using multiple biomarker classes
11,12 - Detects signals associated with multiple cancer types from a single blood draw and expands early detection opportunities, even for aggressive cancers such as pancreatic, liver, lung, and ovarian
11
Connect with us
Let’s discuss how we can support your health system’s cancer screening goals.
Footnotes and references
Important Information about the Cologuard products
The Cologuard test and Cologuard Plus test are indicated to screen adults, 45 years or older, who are at average risk for CRC. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. Not a replacement for colonoscopy in high-risk individuals. False positive and negative results may occur. Rx only. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk- information.
Important Information about the SimpleScreen CRC test
SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Precaution: Based on data from clinical studies, SimpleScreen CRC has limited detection (57%) of Stage I colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy. Rx only. IVD. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk-information.
Developed and manufactured by Freenome, LLC. Distributed by Abbott.
Important Information about the Cancerguard test
The Cancerguard test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. False positive and negative results may occur. The Cancerguard test is a Laboratory Developed Test, it has not been cleared or approved by the US Food and Drug Administration. Rx only. See more at cancerguard.com/indications-for-use.